LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

101.36 1.73

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

98.76

Максимум

101.36

Ключови измерители

By Trading Economics

Приходи

2.9M

-47M

Продажби

16M

49M

Марж на печалбата

-96.144

Служители

283

EBITDA

6.9M

-40M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+12.34% upside

Дивиденти

By Dow Jones

Следващи печалби

4.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

896M

6.9B

Предишно отваряне

99.63

Предишно затваряне

101.36

Настроения в новините

By Acuity

38%

62%

117 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.09.2025 г., 23:37 ч. UTC

Горещи акции

Stocks to Watch: Oracle, Wearable Devices, GameStop

9.09.2025 г., 20:41 ч. UTC

Печалби

Oracle's Backlog Surges With Major Customer Deals in 1Q

9.09.2025 г., 20:30 ч. UTC

Печалби

GameStop 2Q Sales, Profit Rise

9.09.2025 г., 23:19 ч. UTC

Пазарно говорене

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9.09.2025 г., 21:35 ч. UTC

Печалби

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9.09.2025 г., 21:32 ч. UTC

Печалби

Oracle's Backlog Swells With Big Customer Deals -- Update

9.09.2025 г., 21:02 ч. UTC

Придобивния, сливания и поглъщания

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.09.2025 г., 20:33 ч. UTC

Печалби

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9.09.2025 г., 20:26 ч. UTC

Печалби

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9.09.2025 г., 20:23 ч. UTC

Печалби

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9.09.2025 г., 20:12 ч. UTC

Печалби

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9.09.2025 г., 20:10 ч. UTC

Печалби

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9.09.2025 г., 20:10 ч. UTC

Печалби

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9.09.2025 г., 20:09 ч. UTC

Печалби

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9.09.2025 г., 20:09 ч. UTC

Печалби

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9.09.2025 г., 20:08 ч. UTC

Печалби

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9.09.2025 г., 20:08 ч. UTC

Печалби

Oracle 1Q Operating Income Was $4.3 B >ORCL

9.09.2025 г., 20:08 ч. UTC

Печалби

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9.09.2025 г., 20:08 ч. UTC

Печалби

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9.09.2025 г., 20:07 ч. UTC

Печалби

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9.09.2025 г., 20:06 ч. UTC

Печалби

Oracle 1Q Software Revenue $5.72B >ORCL

9.09.2025 г., 20:06 ч. UTC

Печалби

Synopsys 3Q Adj EPS $3.39 >SNPS

9.09.2025 г., 20:06 ч. UTC

Печалби

Oracle 1Q Cloud Revenue $7.19B >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Rev $14.93B >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q EPS $1.01 >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Synopsys 3Q EPS $1.50 >SNPS

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Services Revenue $1.35B >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Adj EPS $1.47 >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Hardware Revenue $670M >ORCL

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

12.34% нагоре

12-месечна прогноза

Среден 112.08 USD  12.34%

Висок 135 USD

Нисък 95 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

13

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

117 / 371 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat